Form 4: Repligen Corp COO James Bylund Reports Stock Transactions

James Bylund, Chief Operating Officer of Repligen Corp, reports acquisition of restricted stock units and stock options, as well as disposition of shares to cover tax obligations.

Summary

• On March 3, 2025, James Bylund, the Chief Operating Officer of Repligen Corporation, reported transactions involving Repligen Corp [RGEN] common stock.
• Bylund acquired 6,435 restricted stock units (RSUs), each representing a contingent right to receive one share of Repligen's common stock, which vest annually over three years starting March 3, 2026.
• He also acquired 6,056 stock options with an exercise price of $155.38, vesting in three equal annual installments starting March 3, 2026, and expiring on March 3, 2035.
• Additionally, 1,239 shares were disposed of at $155.38 to cover tax withholding obligations related to the release of restricted stock units.
• Following these transactions, Bylund directly owns 23,959 shares of common stock and 6,056 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the acquisition of RSUs and stock options, indicating confidence by the COO in the company's future. The sale of shares for tax obligations is a neutral event.

Positives

• The acquisition of restricted stock units and stock options suggests confidence in the company's future performance.

Negatives

• The disposition of shares to cover tax obligations could be perceived as a minor negative, although it's a common practice.

Industry Context

Insider transactions are routinely monitored to gauge executive sentiment and potential future performance of the company. Acquisitions are generally viewed positively, while sales can be interpreted in various ways.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to align management interests with shareholder value.
• The vesting schedules and terms are fairly standard compared to similar companies like Danaher, Thermo Fisher Scientific, and Sartorius.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder sentiment, reflecting confidence from a key executive.

Key Dates